Trial · NCT04126733
Adverse events297
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 297
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Regorafenib Plus Nivolumab | 13 | 70 | 24 |
| other | Hypothyroidism | Endocrine disorders | Regorafenib Plus Nivolumab | 6 | 70 | 6 |
| other | Abdominal distension | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 5 | 70 | 5 |
| other | Abdominal pain | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 15 | 70 | 18 |
| other | Abdominal pain upper | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 7 | 70 | 9 |
| other | Constipation | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 11 | 70 | 12 |
| other | Diarrhoea | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 14 | 70 | 18 |
| other | Dry mouth | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 7 | 70 | 7 |
| other | Nausea | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 16 | 70 | 18 |
| other | Stomatitis | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 11 | 70 | 13 |
| other | Vomiting | Gastrointestinal disorders | Regorafenib Plus Nivolumab | 12 | 70 | 16 |
| other | Asthenia | General disorders | Regorafenib Plus Nivolumab | 4 | 70 | 4 |
| other | Chills | General disorders | Regorafenib Plus Nivolumab | 6 | 70 | 7 |
| other | Fatigue | General disorders | Regorafenib Plus Nivolumab | 30 | 70 | 50 |
| other | Malaise | General disorders | Regorafenib Plus Nivolumab | 4 | 70 | 8 |
| other | Mucosal inflammation | General disorders | Regorafenib Plus Nivolumab | 4 | 70 | 5 |
| other | Oedema peripheral | General disorders | Regorafenib Plus Nivolumab | 6 | 70 | 7 |
| other | Pyrexia | General disorders | Regorafenib Plus Nivolumab | 16 | 70 | 22 |
| other | Bronchitis | Infections and infestations | Regorafenib Plus Nivolumab | 4 | 70 | 5 |
| other | Urinary tract infection | Infections and infestations | Regorafenib Plus Nivolumab | 10 | 70 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04126733/events